You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study

Gasquet, Isabellea; Haro, Josep Mariab; Novick, Diegoc; Edgell, Eric T.d; Kennedy, Liamc; Lepine, Jean Pierree; on behalf of the SOHO Study Group

International Clinical Psychopharmacology:
Original Articles
Abstract

The present study aimed to compare health outcomes and tolerability according to antipsychotic medication (olanzapine, risperidone or an oral typical antipsychotic) after 6 months of treatment in a group of 919 schizophrenic patients who had never previously been treated with antipsychotics. Demographic and clinical predictors of outcome were also identified. Data were extracted from the Schizophrenia Outpatient Health Outcomes (SOHO) study, a prospective, observational study of schizophrenia treatment in 10 European countries. Patients who initiated olanzapine were more likely to have a clinical response than those in the risperidone cohort, and had a greater improvement in quality of life than patients in the risperidone or typical antipsychotic cohorts. High negative and depression symptom scores at baseline and the presence of extrapyramidal symptoms at baseline predicted a worse clinical response, whereas hostile behaviour, paid employment and substance abuse predicted a better clinical outcome. The olanzapine cohort gained more weight than patients in the risperidone cohort, but no significant difference in weight gain was observed between olanzapine and the oral typical antipsychotic cohort. The results should be interpreted conservatively due to the observational study design.

Author Information

aINSERM U669, Hôpital Cochin, AP-HP, Paris, France

bResearch and Development Unit, Sant Joan de Deu-SSM, Sant Boi, Barcelona, Spain

cEli Lilly & Company, Windlesham, Surrey, UK

dEli Lilly & Company, Lilly Corporate Center, Indianapolis, Indiana, USA

eUMR INSERM-CNRS, Hôpital Fernand Widal, AP-HP, Paris, France

Correspondence and requests for reprints to Isabelle Gasquet, INSERM U 669, Maison des Adolescents, Hôpital Cochin, AP-HP, 96 boulevard du Port-Royal, 75679 Paris, Cedex 14, France

Tel: +33 1 40 27 31 85; fax: +33 1 40 27 55 65;

e-mail: isabelle.gasquet@sap.aphp.fr

Received 18 November 2004 Accepted 24 February 2005

© 2005 Lippincott Williams & Wilkins, Inc.